PharVision Advisers’s Nike NKE Stock Holding History

PharVision Advisers’s Portfolio NKE Stock Details NKE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,662	Closed	-$325K	–	903
2025 Q3	$325K	Buy	+4,662	New	+$347K	0.18%	182

Other funds holding NKE

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's NKE Position: Q4 2025 in Review

PharVision Advisers sold out of Nike (NKE) in Q4 2025, closing a stake of 4,662 shares — an estimated $325K sold.

PharVision Advisers first reported a position in NKE in Q3 2025 and held it in 1 quarter. The position peaked at $325K in Q3 2025. 2,060 funds tracked by Wall St. Rank hold NKE as of Q4 2025.

PharVision Advisers reported no remaining Nike position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,662 Nike shares in Q4 2025, an estimated $325K.
PharVision Advisers first reported a position in Nike in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Nike position peaked at $325K in Q3 2025.
2,060 funds tracked by Wall St. Rank held Nike as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.